Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth

分组1 - Myriad Genetics, Inc. reported a strong earnings beat for Q4 2025, with Non-GAAP EPS at $0.04, surpassing consensus estimates [1] - The stock price increased approximately 25% in pre-market trading following the earnings announcement [1] 分组2 - The article emphasizes the importance of combining scientific expertise with financial analysis in the biotech sector [1] - The focus is on identifying innovative biotechnology companies that are developing unique therapies and technologies [1] - The analysis aims to evaluate the science behind drug candidates, competitive landscape, clinical trial design, and market opportunities while considering financial fundamentals [1]